Pyxis Oncology (PYXS) Research & Development (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Research & Development data on file, last reported at $21.7 million in Q4 2025.

• On a quarterly basis, Research & Development rose 54.81% year-over-year to $21.7 million in Q4 2025; TTM through Dec 2025 was $73.7 million, a 25.45% increase from a year earlier, with the FY2025 full-year figure at $73.7 million, up 25.45% from the prior year.
• Research & Development for Q4 2025 stood at $21.7 million, up from $17.8 million in the prior quarter.
• Over the last five years, Research & Development for PYXS reached as high as $32.8 million in Q1 2021 and fell as low as $3.2 million in Q2 2021.
• Historically, Research & Development has averaged $16.0 million across 5 years, with a median of $15.9 million in 2023.
• Across the five-year window, Research & Development surged 435.73% in 2022 and sank 61.12% in 2023, its largest moves.
• Year by year, Research & Development stood at $7.2 million in 2021, then soared by 313.15% to $29.9 million in 2022, then sank by 61.12% to $11.6 million in 2023, then increased by 20.82% to $14.0 million in 2024, then surged by 54.81% to $21.7 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $21.7 million in Q4 2025, $17.8 million in Q3 2025, and $17.1 million in Q2 2025.